Concepedia

Min Yang

MY

Statistics

Publications

13

Citations

1.6K

H-Index

13

Active since

1995

Affiliations

Acetylon Pharmaceuticals (United States)(Current)

Harvard University

Massachusetts General Hospital

Icahn School of Medicine at Mount Sinai

Dana-Farber Cancer Institute

Min Yang is an author at Acetylon Pharmaceuticals (United States) specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1995–2022

13

Publications

13

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 594 citations · Full text

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath et al. · Clinical Cancer Research · 2017 · 246 citations · Full text

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

Andrew J. Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology · 2016 · 193 citations

, , +8

Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin/+ mice

Li Lü, Xiaofei Li, Weilong Zhong et al. · EBioMedicine · 2019 · 146 citations · Full text

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe et al. · Oncotarget · 2016 · 121 citations · Full text

, , +16

1–5 of 13